Showing results (2211-2220 of 13,562) with videos related to
Sort By:
Pageof 1,357
Journal of the Neurological Sciences|September 13, 2011
Morvan's syndrome associated with antibodies to multiple components of the voltage-gated potassium channel complexPanayiotis Loukaides, Natasa Schiza, Philippa Pettingill, et al.Journal of the Neurological Sciences|October 4, 2011
Herpesvirus active replication in multiple sclerosis: a genetic control?Marta Garcia-Montojo, Alfonso Martinez, Virginia De Las Heras, et al.Journal of the Neurological Sciences|October 5, 2011
Administration of edaravone, a free radical scavenger, during t-PA infusion can enhance early recanalization in acute stroke patients--a preliminary studyKazumi Kimura, Juya Aoki, Yuki Sakamoto, et al.Journal of the Neurological Sciences|September 16, 2011
Involvement of the subthalamic nucleus in cognitive functions -- a conceptMarek Baláž, Martina Bočková, Irena Rektorová, et al.Journal of the Neurological Sciences|September 16, 2011
Intracellular bacteria can cause EAE in SJL mice or modify self-specific T cell repertoireChiara Nicolò, Gabriele Di Sante, Giuseppe Migliara, et al.Journal of the Neurological Sciences|October 28, 2011
Visuo-spatial interference affects the identification of emotional facial expressions in unmedicated Parkinson's patientsBeatriz García-Rodríguez, Carmen Casares Guillén, Rosa Jurado Barba, et al.Journal of the Neurological Sciences|June 11, 2011
Cardiac autonomic control in patients with myasthenia gravis and thymomaS Peric, V Rakocevic-Stojanovic, T Nisic, et al.Journal of the Neurological Sciences|June 11, 2011
Quantitative differences in the immunomodulatory effects of Rebif and Avonex in IFN-β 1a treated multiple sclerosis patientsGeorge P Christophi, Jennifer A Christophi, Ross C Gruber, et al.Journal of the Neurological Sciences|June 11, 2011
Neuropsychological correlates of olfactory dysfunction in Parkinson's diseaseJames F Morley, John E DudaJournal of the Neurological Sciences|May 31, 2011
Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon β-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trialJoost Smolders, Raymond Hupperts, Frederik Barkhof, et al.Pageof 1,357